Zobrazeno 1 - 10
of 140
pro vyhledávání: '"ALK, Anaplastic Lymphoma Kinase"'
Autor:
Melania Tesio
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Externí odkaz:
https://doaj.org/article/d6c07bc7cf46415db11ff2aecc40c739
Autor:
Zhe-Rong Zheng, Hsiu-Ying Ku, Kun-Chieh Chen, Chun-Ju Chiang, Chih-Liang Wang, Chih-Yi Chen, Chun-Ming Tsai, Ming-Shyan Huang, Chong-Jen Yu, Jin-Shing Chen, Teh-Ying Chou, Wen-Chung Lee, Chun-Chieh Wang, Tsang-Wu Liu, Jiun-Yi Hsia, Gee-Chen Chang
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionAnaplastic lymphoma kinase (ALK) fusion mutation is more common in younger and never-smoking lung cancer patients. The association of smoking and ALK-tyrosine kinase inhibitors (TKIs) on overall survival (OS) of treatment-naïve ALK-posit
Externí odkaz:
https://doaj.org/article/c3b9b5884b7e45a08b99a9fcc2d49146
Autor:
Woo Kyung Ryu, Hyungkeun Cha, Mi Hwa Park, Jung Soo Kim, Jeong-Seok Choi, Lucia Kim, Kyung-Hee Lee, Hae-Seong Nam
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Crizotinib is an oral selective small-molecular tyrosine kinase inhibitor (TKI) that suppress the activity of anaplastic lymphoma kinase (ALK) and ROS1 kinases, as well as mesenchymal-epithelial transition. The cumulative clinical trials in patients
Externí odkaz:
https://doaj.org/article/b73e9e7bdfab4634bcbd5c44c81f3286
Autor:
Andrea Janikova
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Externí odkaz:
https://doaj.org/article/0a55e440920441eba86824e0a055395e
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Background: Anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) is a rare T-cell neoplasm, accounting for approximately 3% of adult non-Hodgkin lymphomas. Although NPM1 is the most common fusion partner with ALK, many othe
Externí odkaz:
https://doaj.org/article/64b63bc341ac4653b2f2b6c2cbe6c716
Autor:
Carlos A. Torres-Cabala, Valencia Thomas, Penny Fang, Auris Huen, Swaminathan P. Iyer, Roberto N. Miranda, Jonathan L. Curry, Christopher N. Nguyen
Publikováno v:
JAAD Case Reports, Vol 17, Iss, Pp 34-37 (2021)
JAAD Case Reports
JAAD Case Reports
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::680b320ee69b8561db1d0562319ada7a
http://www.sciencedirect.com/science/article/pii/S2352512621006366
http://www.sciencedirect.com/science/article/pii/S2352512621006366
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 11, Iss 3, Pp 750-762 (2021)
Acta Pharmaceutica Sinica. B
Acta Pharmaceutica Sinica. B
The protein tyrosine phosphatase Src homology phosphotyrosyl phosphatase 2 (SHP2) is implicated in various cancers, and targeting SHP2 has become a promising therapeutic approach. We herein described a robust cross-validation high-throughput screenin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::114cd1e4de1acb4de79002f71ffaa0be
https://doi.org/10.1016/j.apsb.2020.10.021
https://doi.org/10.1016/j.apsb.2020.10.021
Autor:
Lucía Prieto Santamaría, Alejandro Rodríguez-González, Marina Díaz Uzquiano, Esther Ugarte Carro, Yuliana Pérez Gallardo, Ernestina Menasalvas Ruiz
Publikováno v:
Computational and Structural Biotechnology Journal
Computational and Structural Biotechnology Journal, Vol 19, Iss, Pp 4559-4573 (2021)
Computational and Structural Biotechnology Journal, Vol 19, Iss, Pp 4559-4573 (2021)
Graphical abstract
Drug repurposing has become a widely used strategy to accelerate the process of finding treatments. While classical de novo drug development involves high costs, risks, and time-consuming paths, drug repurposing allows to reus
Drug repurposing has become a widely used strategy to accelerate the process of finding treatments. While classical de novo drug development involves high costs, risks, and time-consuming paths, drug repurposing allows to reus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0161caf3f0dc9bcf4a7eacdbdeed248
https://doi.org/10.1016/j.csbj.2021.08.003
https://doi.org/10.1016/j.csbj.2021.08.003
Publikováno v:
International Journal of Surgery Case Reports
Highlights • Pulmonary lymphoepithelioma-like carcinoma (LELC) is extremely rare in Japan. • None of the studies regarding LELC in Japan described an association with PD-L1. • This is the first case of LELC in Japan with both expression of EBER
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::455391633697daa1cd3a358aa64da240
http://europepmc.org/articles/PMC7851415
http://europepmc.org/articles/PMC7851415
Publikováno v:
Radiology Case Reports
Radiology Case Reports, Vol 16, Iss 3, Pp 504-510 (2021)
Radiology Case Reports, Vol 16, Iss 3, Pp 504-510 (2021)
Inflammatory myofibroblastic tumors (IMT) are rare soft tissue tumors of intermediate malignant potential with tendency for local recurrence. Although they can occur at all age groups, occurrence in infants is extremely unusual and their imaging char
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd66dbb93e3de164cd59bed128bd338f
http://europepmc.org/articles/PMC7753227
http://europepmc.org/articles/PMC7753227